Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Nausea 12Vomiting 11Neoplasms 7Hematologic Neoplasms 5Anorexia 4Cachexia 3Breast Neoplasms 3Weight Loss 2Stomach Neoplasms 2Advanced Cancer 2Testicular Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Sedentary Behavior 1Prosthesis Failure 1Postoperative Nausea and Vomiting 1Pain 1Opioid-Related Disorders 1Nutrition Disorders 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Muscular Atrophy 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Lung Neoplasms 1Insulin Resistance 1Hyperlipidemias 1Hyperglycemia 1Gynecologic Cancer 1Esophageal Neoplasms 1

Interventions

Surveys and Questionnaires 7Standard of Care 5Sirolimus 5Bevacizumab 5temsirolimus 4Interviews as Topic 4Paclitaxel 3olaparib 2Vorinostat 2Olanzapine 2Magnetic Resonance Spectroscopy 2Gemcitabine 2Everolimus 2Erlotinib Hydrochloride 2Dasatinib 2Cetuximab 2zaleplon 1vistusertib 1tilsotolimod 1pazopanib 1olanzapine-fluoxetine combination 1nimotuzumab 1liposomal doxorubicin 1capivasertib 1apatinib 1Videotape Recording 1Vemurafenib 1Valproic Acid 1Trastuzumab 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Advanced Cancer × Olanzapine × Clear all
NCT06338683 2024-03-29

Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer

Qinghai Red Cross Hospital

Phase 3 Recruiting
230 enrolled

Advanced Cancer

NCT00512291 2011-09-27

Subcutaneous Olanzapine for Hyperactive or Mixed Delirium

M.D. Anderson Cancer Center

Phase NA Completed
25 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡